Dietary Capsaicin Reduces Obesity‐induced Insulin Resistance and Hepatic Steatosis in Obese Mice Fed a High‐fat Diet

  title={Dietary Capsaicin Reduces Obesity‐induced Insulin Resistance and Hepatic Steatosis in Obese Mice Fed a High‐fat Diet},
  author={Ji-Hye Kang and Goto Tsuyoshi and I S Han and Teruo Kawada and Young Min Kim and Rina Yu},
Obesity‐induced inflammation contributes to the development of obesity‐related metabolic disorders such as insulin resistance, type 2 diabetes, fatty liver disease, and cardiovascular disease. In this study, we investigated whether dietary capsaicin can reduce obesity‐induced inflammation and metabolic disorders such as insulin resistance and hepatic steatosis. Male C57BL/6 obese mice fed a high‐fat diet for 10 weeks received a supplement of 0.015% capsaicin for a further 10 weeks and were… 

Transient receptor potential vanilloid type‐1 channel regulates diet‐induced obesity, insulin resistance, and leptin resistance

  • E. LeeD. Jung Jason K. Kim
  • Biology
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2015
The results indicate that lacking TRPV1 exacerbates the obesity and insulin resistance associated with an HFD and aging, and suggest that TRpV1 has a major role in regulating glucose metabolism and hypothalamic leptin's effects in obesity.

Histidine supplementation alleviates inflammation in the adipose tissue of high-fat diet-induced obese rats via the NF-κB- and PPARγ-involved pathways

The findings indicate that histidine is an effective candidate for ameliorating inflammation and oxidative stress in obese individuals via the NF-κB- and PPARγ-involved pathways.

Sasa veitchii extract reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet

It is demonstrated that SE may reduce obesity-induced glucose and insulin tolerance, not only by suppressing inflammatory responses but also by improving insulin signaling.

Sex-Specific Protection Against Diet-Induced Non-Alcoholic Fatty Liver Disease in TRPV1 Null Mice

The data suggest that loss of TRPV1 promotes fat accumulation, NAFLD development and changes in liver lipid profiles in male mice, the extent to which is less severe in female V1KO mice.

Salvianolic Acid B Inhibited PPARγ Expression and Attenuated Weight Gain in Mice with High-Fat Diet-Induced Obesity

The data suggest that Sal B may reduce obesity and obesity-related metabolic disorders by suppressing adipogenesis and the effects of Sal B in adipose tissue may be related to its action on PPARγ, C/EBPα, GATA-2 and GATA3.

Dietary Capsaicin Improves Glucose Homeostasis and Alters the Gut Microbiota in Obese Diabetic ob/ob Mice

The beneficial effects of dietary capsaicin on glucose homeostasis are likely associated with the alterations of specific bacteria at the genus level, and contribute to improved glucoseHomeostasis through increasing short-chain fatty acids, regulating gastrointestinal hormones and inhibiting pro-inflammatory cytokines.

Capsaicin-induced transcriptional changes in hypothalamus and alterations in gut microbial count in high fat diet fed mice.

Dietary capsaicin and antibiotics act synergistically to reduce non-alcoholic fatty liver disease induced by high fat diet in mice

Results suggest the co-treatment of capsaicin and antibiotics, a novel combination strategy, would play synergistically to attenuate the HFD-induced obesity, fatty liver and metabolic disorder.

Effects of Capsaicin Coadministered with Eicosapentaenoic Acid on Obesity-Related Dysregulation in High-Fat-Fed Mice.

The study suggests that the combination of EPA and capsaicin might be beneficial for delaying the progression of obesity-related metabolic dysregulation and subsequent complications.



Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity.

It is concluded that orally ingested curcumin reverses many of the inflammatory and metabolic derangements associated with obesity and improves glycemic control in mouse models of type 2 diabetes.

Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation.

It is suggested that PPARalpha protects against obesity-induced chronic inflammation in liver by reducing hepatic steatosis, by direct down-regulation of inflammatory genes, and by attenuating inflammation in adipose tissue.

PPARs, Obesity, and Inflammation

The role of PPARs in obesity-induced inflammation specifically in adipose tissue, liver, and the vascular wall is addressed, with a growing recognition that obesity represents a state of chronic low-level inflammation.

Protection from obesity-induced insulin resistance in mice lacking TNF-α function

Results indicate that TNF-α is an important mediator of insulin resistance in obesity through its effects on several important sites of insulin action.

Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation

Anti-inflammatory mechanisms as contributors to the beneficial metabolic effects of PPAR activation are also worth considering for the following reasons: obesity and insulin resistance are associated with a proinflammatory milieu.

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.

It is proposed that obesity-related insulin resistance is, at least in part, a chronic inflammatory disease initiated in adipose tissue, and that macrophage-related inflammatory activities may contribute to the pathogenesis of obesity-induced insulin resistance.

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity.

It is suggested that an increase in MCP-1 expression in adipose tissue contributes to the macrophage infiltration into this tissue, insulin resistance, and hepatic steatosis associated with obesity in mice.

A novel PPAR (cid:1) agonist ameliorates insulin resistance in dogs fed a high-fat diet

KRP-101 administration resulted in a significantly lower weight of overall visceral fat, which is associated with increased adiponectin and decreased leptin in serum, which suggests the use of potent and subtype-selective PPAR (cid:1) agonists as a potentially relevant therapeutic approach to treat human insulin resistance associated with visceral obesity.

Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.

Altered physiology of adipose tissue is central to development of IR, metabolic syndrome and NAFLD and insulin resistance plays a key role in its pathogenesis.